Molecular markers and targets for colorectal cancer prevention
暂无分享,去创建一个
[1] Graeme J. Poston,et al. β‐catenin expression in primary and metastatic colorectal carcinoma , 1999 .
[2] B. Calvo,et al. Expression of 15-lipoxygenase-1 in human colorectal cancer. , 1999, Cancer research.
[3] Michael Z Michael,et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. , 2003, Molecular cancer research : MCR.
[4] M. Brandi,et al. Growth response of colon cancer cell lines to selective estrogen receptor modulators. , 2003, Anticancer research.
[5] Rivat Christine,et al. Implication of STAT3 Signaling in Human Colonic Cancer Cells during Intestinal Trefoil Factor 3 (TFF3) – and Vascular Endothelial Growth Factor–Mediated Cellular Invasion and Tumor Growth , 2005, Cancer Research.
[6] Henk-Jan Guchelaar,et al. The risk of cancer in users of statins. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] C. Croce,et al. MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.
[8] C. Rao,et al. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. , 2004, Molecular cancer therapeutics.
[9] G. Crosthwaite,et al. Proton pump inhibitors for Barrett's oesophagus , 2000, Gut.
[10] D. Witte,et al. Estrogen receptor β is expressed in human colorectal adenocarcinoma , 2001 .
[11] J M Alvaro-Gracia,et al. Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. , 2004, Rheumatology.
[12] F. Russo,et al. Prognostic value of cytosolic estrogen receptors in human colorectal carcinoma and surrounding mucosa , 1994, Digestive Diseases and Sciences.
[13] A. Lewis,et al. Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta. , 2002, The Journal of endocrinology.
[14] D. Ritchie,et al. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. , 1997, Prostaglandins, leukotrienes, and essential fatty acids.
[15] F. Slack,et al. Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.
[16] R. Bernards,et al. Stable suppression of tumorigenicity by virus-mediated RNA interference. , 2002, Cancer cell.
[17] Elizabeth L. Barry,et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. , 2007, JAMA.
[18] F. Traganos,et al. Nitric Oxide-Donating Nonsteroidal Anti-Inflammatory Drugs Inhibit the Growth of Various Cultured Human Cancer Cells: Evidence of a Tissue Type-Independent Effect , 2002, Journal of Pharmacology and Experimental Therapeutics.
[19] P. Lakatos,et al. Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers. , 2001, European journal of cancer.
[20] J. Mason. Statins and their role in vascular protection. , 2003, Clinical science.
[21] Ronit Almog,et al. Statins and the risk of colorectal cancer. , 2005, The New England journal of medicine.
[22] H. Herschman. Prostaglandin synthase 2. , 1996, Biochimica et biophysica acta.
[23] Y. Kawasaki,et al. Wnt/β-Catenin and Estrogen Signaling Converge in Vivo* , 2004, Journal of Biological Chemistry.
[24] D. Levy,et al. What does Stat3 do? , 2002, The Journal of clinical investigation.
[25] R. DuBois,et al. Cyclooxygenase, NSAIDs, and colorectal cancer , 1996, Journal of Gastroenterology.
[26] M. Gottardis,et al. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. , 1998, Cancer research.
[27] I. J. Lynch,et al. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. , 2001, Cancer research.
[28] F. Grodstein,et al. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. , 1999, The American journal of medicine.
[29] R. Evans,et al. Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.
[30] V. Steele,et al. Is inducible nitric oxide synthase a target for chemoprevention? , 2003, Molecular cancer therapeutics.
[31] 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. , 2005 .
[32] R. DuBois,et al. Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.
[33] Xi He,et al. Adenomatous Polyposis Coli (APC) Differentially Regulates β-Catenin Phosphorylation and Ubiquitination in Colon Cancer Cells* , 2006, Journal of Biological Chemistry.
[34] H. Paulson,et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia , 2004, Nature Medicine.
[35] K. Shirai,et al. [HMG-CoA reductase]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.
[36] C. la Vecchia,et al. Hormone replacement therapy and risk of colon and rectal cancer. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[37] T. P. Pretlow,et al. Aberrant crypts in human colonic mucosa: Putative preneoplastic lesions , 1992, Journal of cellular biochemistry. Supplement.
[38] Shan Wang,et al. Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. , 2004, World journal of gastroenterology.
[39] L. Hamann,et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists , 1997, Nature.
[40] M. Shinoda,et al. Effects of ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor, on indices of early articular lesion in MRL/MpJ-lpr/lpr mice , 1999, Inflammation Research.
[41] R. Poulsom,et al. Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse. , 2001, Gastroenterology.
[42] N. Pommery,et al. COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy. , 2007, Current topics in medicinal chemistry.
[43] M. Thun,et al. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. , 1995, Journal of the National Cancer Institute.
[44] Michael A. Beer,et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. , 2007, Molecular cell.
[45] M. Kitagawa,et al. Geranylgeranylated Rho Small GTPase(s) Are Essential for the Degradation of p27Kip1 and Facilitate the Progression from G1 to S Phase in Growth-stimulated Rat FRTL-5 Cells* , 1997, The Journal of Biological Chemistry.
[46] S. Singh,et al. Oestrogen and colonic epithelial cell growth. , 1995, Gut.
[47] Bert Vogelstein,et al. Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer , 1998 .
[48] P. Opolon,et al. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. , 2002, Biochemical and biophysical research communications.
[49] L. Patterson,et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy , 2004, Journal of Family Planning and Reproductive Health Care.
[50] Norman Wolmark,et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.
[51] M. Morrow. Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial , 2007 .
[52] S. Schwartz,et al. Colorectal cancer following tamoxifen therapy for breast cancer (United States) , 2001, Cancer Causes & Control.
[53] G. Landberg,et al. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. , 2003, Gastroenterology.
[54] Xiao-Fan Wang,et al. Inhibition of the 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Pathway Induces p53-independent Transcriptional Regulation of p21 WAF1/CIP1 in Human Prostate Carcinoma Cells* , 1998, The Journal of Biological Chemistry.
[55] H Jick,et al. Statin use and cancer risk in the General Practice Research Database , 2004, British Journal of Cancer.
[56] J. Abbruzzese,et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis , 2003, Oncogene.
[57] R. Chandraratna,et al. Adenomatous Polyposis Coli (APC)-independent Regulation of β-Catenin Degradation via a Retinoid X Receptor-mediated Pathway* , 2003, Journal of Biological Chemistry.
[58] J. Turkson,et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.
[59] J. Potter,et al. Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States , 1997, Cancer Causes & Control.
[60] Walter Birchmeier,et al. Hot papers in cell biology - J. Behrens, J.P. von Kries, M. Kuehl, L. Bruhn, D. Wedlich, R. Grosschedl, W. Birchmeier: "Functional interaction of beta-catenin with the transcription factor LEF-1" - Comments by Walter Birchmeier , 1999 .
[61] Analysis of gene expression profile in colon cancer using the Cancer Genome Anatomy Project and RNA interference. , 2006, Chinese journal of digestive diseases.
[62] Jianjun Gao,et al. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. , 2006, Cancer research.
[63] Tom S. Price,et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. , 2006, Gastroenterology.
[64] B. Rigas,et al. Altered eicosanoid levels in human colon cancer. , 1993, The Journal of laboratory and clinical medicine.
[65] A. Sjölander,et al. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. , 2000, Gastroenterology.
[66] A. Ford-hutchinson,et al. Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissues , 1993, FEBS letters.
[67] T. Hoey,et al. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the β-catenin pathway , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[68] S. Cummings,et al. Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[69] M. Sporn,et al. Chemoprevention: an essential approach to controlling cancer , 2002, Nature Reviews Cancer.
[70] C. Harris,et al. Nitric oxide in cancer and chemoprevention. , 2003, Free radical biology & medicine.
[71] J. Gustafsson,et al. Role of estrogen receptor β in colonic epithelium , 2006 .
[72] Roy Garcia,et al. STATs in oncogenesis , 2000, Oncogene.
[73] J. Fraumeni,et al. A prospective study of menopausal hormones and risk of colorectal cancer (United States) , 1997, Cancer Causes & Control.
[74] R. Frairia,et al. Sex steroid receptors, secondary bile acids and colorectal cancer. A possible mechanism of interaction. , 2003, Panminerva medica.
[75] Michael Kühl,et al. Functional interaction of β-catenin with the transcription factor LEF-1 , 1996, Nature.
[76] J. Castle,et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs , 2005, Nature.
[77] J. Barkin. The Use of Aspirin for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force , 2008 .
[78] C. Watson,et al. Membrane estrogen receptor-α levels predict estrogen-induced ERK1/2 activation in MCF-7 cells , 2004, Breast Cancer Research.
[79] K. Gunsalus,et al. Combinatorial microRNA target predictions , 2005, Nature Genetics.
[80] V. Steele,et al. Nitric oxide–releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets , 2006, Molecular Cancer Therapeutics.
[81] L. Looijenga,et al. Molecular characterization of hiwi, a human member of the piwi gene family whose overexpression is correlated to seminomas , 2002, Oncogene.
[82] C. Shou,et al. Expression of hiwi gene in human gastric cancer was associated with proliferation of cancer cells , 2006, International journal of cancer.
[83] Akira Kikuchi,et al. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK‐3β and β‐catenin and promotes GSK‐3β‐dependent phosphorylation of β‐catenin , 1998 .
[84] C. Croce,et al. MicroRNA-cancer connection: the beginning of a new tale. , 2006, Cancer research.
[85] M. von Knebel Doeberitz,et al. Wnt/β‐catenin‐pathway as a molecular target for future anti‐cancer therapeutics , 2005 .
[86] Frank Petersen,et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .
[87] Chao Zhang,et al. RNAi technology: a revolutionary tool for the colorectal cancer therapeutics. , 2006, World journal of gastroenterology.
[88] N. Pommery,et al. Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity. , 2006, Anti-cancer agents in medicinal chemistry.
[89] Richard G. W. Anderson,et al. ERβ Has Nongenomic Action in Caveolae , 2002 .
[90] B. Rigas,et al. The Role of NSAIDs in the Prevention of Colon Cancer , 2002, Cancer investigation.
[91] Wei Jiang,et al. Wnt/beta-catenin signaling pathway as a novel cancer drug target. , 2004, Current cancer drug targets.
[92] Robert A Hegele,et al. Retinoid X receptor heterodimers in the metabolic syndrome. , 2005, The New England journal of medicine.
[93] J. Darnell,et al. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[94] Shuji Ogino,et al. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.
[95] S. Hart,et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. , 1992, The Journal of biological chemistry.
[96] W. Smith. Prostanoid biosynthesis and mechanisms of action. , 1992, The American journal of physiology.
[97] A. Papavassiliou,et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. , 2003, European journal of cancer.
[98] C. Rao,et al. Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis. , 2002, Cancer detection and prevention.
[99] H. Johansson,et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. , 1995, Journal of the National Cancer Institute.
[100] Wei Zhang,et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. , 2005, The American journal of pathology.
[101] L. Ellis,et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.
[102] B. Katzenellenbogen,et al. Estrogen receptors: selective ligands, partners, and distinctive pharmacology. , 2000, Recent progress in hormone research.
[103] S. Rutberg,et al. Loss of retinoic acid receptors in mouse skin and skin tumors is associated with activation of the ras(Ha) oncogene and high risk for premalignant progression. , 1996, Cancer research.
[104] W. Birchmeier,et al. New aspects of Wnt signaling pathways in higher vertebrates. , 2001, Current opinion in genetics & development.
[105] Amy A. Caudy,et al. Post-transcriptional gene silencing by double-stranded RNA , 2001, Nature Reviews Genetics.
[106] R. DuBois,et al. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. , 1996, Gastroenterology.
[107] A. Hatzigeorgiou,et al. A combined computational-experimental approach predicts human microRNA targets. , 2004, Genes & development.
[108] C. Burge,et al. Prediction of Mammalian MicroRNA Targets , 2003, Cell.
[109] K. Kashfi,et al. Nitric oxide-donating aspirin inhibits β-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear β-catenin–TCF association , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[110] Y. Vodovotz,et al. The role of nitric oxide chemistry in cancer treatment. , 1998, Biochemistry. Biokhimiia.
[111] R. Thampan,et al. Membrane associated estrogen receptors and related proteins: Localization at the plasma membrane and the endoplasmic reticulum , 2003, Molecular and Cellular Biochemistry.
[112] K. Korach,et al. Estrogen receptors and human disease. , 2006, The Journal of clinical investigation.
[113] P. Newcomb,et al. POSTMENOPAUSAL HORMONE USE AND RISK OF LARGE-BOWEL CANCER , 1996 .
[114] J. Darnell,et al. Stat3 as an Oncogene , 1999, Cell.
[115] R. Wolff,et al. Associations between ERα, ERβ, and AR Genotypes and Colon and Rectal Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.
[116] T. Morisaki,et al. Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue , 1999, Journal of surgical oncology.
[117] M. Yasuno,et al. Expression of 5-lipoxygenase in human colorectal cancer. , 2006, World journal of gastroenterology.
[118] H. Friess,et al. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. , 2003, Cancer research.
[119] Ming Jiang,et al. Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. , 2003, Genes & development.
[120] E. Levin,et al. Integration of the extranuclear and nuclear actions of estrogen. , 2005, Molecular endocrinology.
[121] C. Burge,et al. Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.
[122] Rajnish A. Gupta,et al. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.
[123] S. Narayan,et al. Estradiol is trophic for colon cancer in mice: effect on ornithine decarboxylase and c-myc messenger RNA. , 1992, Gastroenterology.
[124] J. Dogné,et al. New trends in dual 5-LOX/COX inhibition. , 2002, Current medicinal chemistry.
[125] R. DuBois,et al. New paradigms for cancer prevention. , 2001, Carcinogenesis.
[126] W. Birchmeier,et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. , 1998, Science.
[127] M. Schwab,et al. Cyclooxygenase-2 Expression in Human Colorectal Cancer Is Unrelated to Overall Patient Survival , 2005, Clinical Cancer Research.
[128] R. Chandraratna,et al. Enantioselective syntheses of potent retinoid X receptor ligands: differential biological activities of individual antipodes. , 2001, Journal of medicinal chemistry.
[129] J. Soria,et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. , 2001, Carcinogenesis.
[130] M. Kondo,et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.
[131] C. Elson,et al. Sterol‐independent regulation of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase in tumor cells , 2001, Molecular carcinogenesis.
[132] 林下 陽二. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation , 2006 .
[133] Marc A Pfeffer,et al. Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.
[134] S. Hilsenbeck,et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[135] J. Auwerx,et al. Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (Rxr)/Peroxisome Proliferator–Activated Receptor γ (Pparγ) Heterodimer , 2001, The Journal of experimental medicine.
[136] T. Hoey,et al. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[137] B. Rigas,et al. Nitric Oxide-Donating Aspirin Inhibits Colon Cancer Cell Growth via Mitogen-Activated Protein Kinase Activation , 2006, Journal of Pharmacology and Experimental Therapeutics.
[138] J. Morrow,et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. , 1997, The Journal of clinical investigation.
[139] J. Goldstein,et al. Regulation of the mevalonate pathway , 1990, Nature.
[140] C. Harris,et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. , 1998, Cancer research.
[141] M. Crisby. Modulation of the inflammatory process by statins. , 2003, Drugs of today.
[142] R. Goldbohm,et al. Dietary folate and APC mutations in sporadic colorectal cancer. , 2006, The Journal of nutrition.
[143] John Robbins,et al. National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.
[144] J. Darnell,et al. Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.
[145] J. Turkson,et al. Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.
[146] P. Wright,et al. Flavopiridol Sensitivity of Cancer Cells Isolated from Ascites and Pleural Fluids , 2005, Clinical Cancer Research.
[147] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[148] Kurt Zatloukal,et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. , 2005, Neoplasia.
[149] Colleen C Nelson,et al. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? , 2005, Endocrine reviews.
[150] R. Jove,et al. Cooperative Regulation of Mcl-1 by Janus Kinase/STAT and Phosphatidylinositol 3-Kinase Contribute to Granulocyte-Macrophage Colony-Stimulating Factor-Delayed Apoptosis in Human Neutrophils1 , 2001, The Journal of Immunology.
[151] K. Kashfi,et al. Nitric-oxide-donating NSAIDs as agents for cancer prevention. , 2004, Trends in molecular medicine.
[152] Barry R. Davis,et al. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.
[153] Michael J Thun,et al. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. , 2006, Journal of the National Cancer Institute.
[154] M. Sporn,et al. Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia , 2002 .
[155] S. Moochhala,et al. Nitric oxide synthase activity and expression in human colorectal cancer. , 1996, Carcinogenesis.
[156] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[157] K. Fransén,et al. Nitric oxide synthase 2 mRNA expression in relation to p53 and adenomatous polyposis coli mutations in primary colorectal adenocarcinomas. , 2002, Surgery.
[158] E. Miska,et al. How microRNAs control cell division, differentiation and death. , 2005, Current opinion in genetics & development.
[159] Brian S. Roberts,et al. The colorectal microRNAome. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[160] D F Roychowdhury,et al. Aspirin and the risk of colorectal cancer in women. , 1996, The New England journal of medicine.
[161] Garret A FitzGerald,et al. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.
[162] C. Rao,et al. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. , 1999, Carcinogenesis.
[163] Robert Riddell,et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.
[164] Christian Bogdan,et al. Nitric oxide and the immune response , 2001, Nature Immunology.
[165] B Getty,et al. beta-catenin expression in primary and metastatic colorectal carcinoma. , 1999, International journal of cancer.
[166] Eva Enmark,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Human Estrogen Receptor �-Gene Structure, Chromosomal Localization, and Expression Pattern* , 2022 .
[167] D. Bartel,et al. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs , 2004, Nature Reviews Genetics.
[168] William L. Smith,et al. The Membrane Binding Domains of Prostaglandin Endoperoxide H Synthases 1 and 2 , 1999, The Journal of Biological Chemistry.
[169] R. Hoover,et al. EVIDENCE OF A HEALTHY ESTROGEN USER SURVIVOR EFFECT , 1995, Epidemiology.
[170] C. Rao,et al. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. , 2002, International journal of oncology.
[171] M. Drews,et al. Molecular study of sex steroid receptor gene expression in human colon and in colorectal carcinomas , 1997, Journal of surgical oncology.
[172] L. Williams,et al. Bridging of β-catenin and glycogen synthase kinase-3β by Axin and inhibition of β-catenin-mediated transcription , 1998 .
[173] Julian Peto,et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.
[174] A. Umezawa,et al. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. , 1994, Carcinogenesis.
[175] Hans Clevers,et al. Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC , 1997, Science.
[176] Jianjun Gao,et al. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[177] I. Charles,et al. Microencapsulated iNOS‐expressing cells cause tumor suppression in mice , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[178] V. Speirs,et al. Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. , 2005, Oncology reports.
[179] S. LeVine,et al. Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase , 2004, Brain Research.
[180] Jie-ping Yu,et al. Expression of estrogen receptor beta in human colorectal cancer. , 2004, World journal of gastroenterology.
[181] M. Bertagnolli,et al. Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer. , 2004, Carcinogenesis.
[182] L. Marnett. Aspirin and the potential role of prostaglandins in colon cancer. , 1992, Cancer research.
[183] M. Hamberg,et al. Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases. , 1976, The Journal of biological chemistry.
[184] F. Vizoso,et al. Estrogen and Progesterone Receptors in Colorectal Cancer and Surrounding Mucosa , 2001, The International journal of biological markers.
[185] R. Evans,et al. Nuclear receptor that identifies a novel retinoic acid response pathway , 1990, Nature.
[186] William K K Wu,et al. A mechanistic study of colon cancer growth promoted by cigarette smoke extract. , 2005, European journal of pharmacology.
[187] Leah E. Mechanic,et al. Nitric Oxide, a Mediator of Inflammation, Suppresses Tumorigenesis , 2004, Cancer Research.
[188] D. Moher,et al. Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force , 2007, Annals of Internal Medicine.
[189] Y. Akao,et al. MicroRNA-143 and -145 in colon cancer. , 2007, DNA and cell biology.
[190] W. Wu,et al. Nicotine Promoted Colon Cancer Growth via Epidermal Growth Factor Receptor, c-Src, and 5-Lipoxygenase-Mediated Signal Pathway , 2004, Journal of Pharmacology and Experimental Therapeutics.
[191] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[192] X. Agirre,et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues , 2006, Molecular Cancer.
[193] T. Narisawa,et al. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. , 1996, The Tohoku journal of experimental medicine.
[194] R. Coffey,et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.
[195] S. Nozawa,et al. Expression of estrogen receptor beta in rat bone. , 1997, Endocrinology.
[196] Junji Kato,et al. Aberrant Crypt Foci of the Colon as Precursors of Adenoma and Cancer , 1998 .
[197] J. Bromberg. Stat proteins and oncogenesis. , 2002, The Journal of clinical investigation.
[198] Anton J. Enright,et al. Human MicroRNA Targets , 2004, PLoS biology.
[199] S. Moochhala,et al. Aberrant expression of nitric oxide synthase in human polyps, neoplastic colonic mucosa and surrounding peritumoral normal mucosa. , 1994, Carcinogenesis.
[200] B. Katzenellenbogen,et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[201] K. Umesono,et al. A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR , 1991, Cell.
[202] V. Steele,et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. , 2006, Cancer research.
[203] S. Hammond,et al. MicroRNAs as oncogenes. , 2006, Current opinion in genetics & development.
[204] C. Rao,et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. , 1999, Gastroenterology.
[205] M. Lipkin,et al. Preclinical Mouse Models for Cancer Chemoprevention Studies , 1999, Annals of the New York Academy of Sciences.
[206] Francesca Benedini,et al. Positional Isomerism Markedly Affects the Growth Inhibition of Colon Cancer Cells by Nitric Oxide-Donating Aspirin in Vitro and in Vivo , 2005, Journal of Pharmacology and Experimental Therapeutics.
[207] Harry K. Genant,et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .
[208] T. Narisawa,et al. Chemoprevention by Pravastatin, a 3‐Hydroxy‐3‐methylglutaryl‐coenzyme A Reductase Inhibitor, of N‐Methyl‐N‐nitrosourea‐induced Colon Carcinogenesis in F344 Rats , 1996, Japanese journal of cancer research : Gann.
[209] R. Nusse,et al. Wnt signaling: a common theme in animal development. , 1997, Genes & development.
[210] S. Kansra,et al. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release , 2005, Molecular and Cellular Endocrinology.
[211] W P Bennett,et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. , 1999, Journal of the National Cancer Institute.
[212] K. Hahm,et al. Decreased Helicobacter pylori associated gastric carcinogenesis in mice lacking inducible nitric oxide synthase , 2004, Gut.
[213] R. Evans,et al. The RXR heterodimers and orphan receptors , 1995, Cell.
[214] Paul Polakis,et al. Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly , 1996, Science.
[215] P. Knekt,et al. Dietary fat, cholesterol and colorectal cancer in a prospective study , 2001, British Journal of Cancer.
[216] B. Bapat,et al. Cyclooxygenase-2 knockdown by RNA interference in colon cancer. , 2006, International journal of oncology.
[217] R. DuBois,et al. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[218] R. White,et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[219] Gregor Eichele,et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor , 1992, Cell.
[220] H. Harn,et al. Expression of nuclear retinoid receptors in normal, premalignant and malignant gastric tissues determined by in situ hybridization , 1999, British Journal of Cancer.
[221] J. Bertram,et al. Tamoxifen inhibits colorectal cancer metastases in the liver: A study in a murine model , 1998, Journal of gastroenterology and hepatology.
[222] N. Dean,et al. Antisense oligonucleotide-based therapeutics for cancer , 2003, Oncogene.
[223] P K Lala,et al. Role of nitric oxide in carcinogenesis and tumour progression. , 2001, The Lancet. Oncology.
[224] K. Kinzler,et al. Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.
[225] J. Pelletier,et al. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs , 2003, Annals of the rheumatic diseases.
[226] J. Olsen,et al. Cancer risk among statin users: A population‐based cohort study , 2005, International journal of cancer.
[227] G. Piazza,et al. Combinatorial chemoprevention: efficacy of lovostatin and exisulind on the formation and progression of aberrant crypt foci. , 2004, Anticancer research.
[228] I. L. Smith,et al. Pharmacokinetics and Pharmacodynamics of Tepoxalin after Single Oral Dose Administration to Healthy Volunteers , 1996, Journal of clinical pharmacology.
[229] K. Seibert,et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.
[230] R Grosschedl,et al. Functional interaction of beta-catenin with the transcription factor LEF-1. , 1996, Nature.
[231] Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib After Cardiac Surgery , 2005 .
[232] J. LeLorier,et al. Do statins cause cancer? A meta-analysis of large randomized clinical trials. , 2001, The American journal of medicine.
[233] D. Beer,et al. Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis , 2004, Clinical Cancer Research.
[234] L. Blais,et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. , 2000, Archives of internal medicine.
[235] A. Jazaeri,et al. Selective loss of estrogen receptor β in malignant human colon , 2000 .
[236] M. Pignatelli,et al. β-catenin - A linchpin in colorectal carcinogenesis? , 2002 .
[237] C. Rao,et al. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. , 2002, Cancer research.
[238] F. Traganos,et al. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? , 2004, Biochemical pharmacology.
[239] Bert Vogelstein,et al. APC mutations occur early during colorectal tumorigenesis , 1992, Nature.
[240] J. Stein,et al. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. , 2001, Carcinogenesis.
[241] Richard Graham Knowles,et al. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. , 1997, Cancer research.
[242] H. Ohshima,et al. Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production. , 2001, Cancer research.
[243] C. Serhan,et al. Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. , 2001, The American journal of pathology.
[244] B Vojnovic,et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. , 2001, Cancer research.
[245] B. Kimler,et al. Selective estrogen-receptor modulators for primary prevention of breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[246] Dahlén,et al. Leukotrienes as targets for treatment of asthma and other diseases. Current basic and clinical research , 2000, American journal of respiratory and critical care medicine.
[247] C C Glüer,et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.